It is well accepted among health economics wonks that the lion’s share of pharmaceutical company profits come when these companies hold exclusive rights to their products. Once their blockbuster pills go “generic,” competitors enter the marketplace and profits plummet. Consider captopril, a groundbreaking heart failure medication introduced in the early 80s by Bristol-Myers Squibb under…
Steve B. wasn’t going to be fooled twice. He’d recently seen an ear, nose, and throat specialist for a “tickle in the throat” that wouldn’t go away. He’d forked over a co-pay at check-in, but then the doctor said he needed “to put a scope down there” and check his throat. He later received a…
Latuda is a drug to treat schizophrenia. It costs about $4,000 per month in the U.S. In Canada, the price is closer to $500.
Ibrance, a breast cancer drug, costs $10,000 more per month in the U.S. than in Canada.
Why these enormous price differences?
Your physician has received generous money from one of the companies that manufacture the robots. Consciously or unconsciously, that money could be influencing her recommendation. The positivity of physicians’ comments on X rises significantly among those receiving the most generous industry payments. Read more here.
Here is a blog post I wrote for the Hastings Center, laying out some hopeful thoughts about how we can use Medicaid crises, which are occurring in so many states right now, to figure out how to control health care costs.
In response to the New England Journal article I published with Yousuf Zafar and Amy Abernethy, Newsweek chimed in this week with a report on the topic, including some thoughtful commentary from other medical experts. I thought it was worth pointing you towards this article, in part to remind you that Newsweek still exists, and…